Sartorius sharpens its brand focus

The company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster.
Sartorius has revised its brand look with a new brand promise, a new logo and new colours.
At the focus of this relaunch is Sartorius’ new brand promise that it summarizes in its new claim: Simplifying Progress. With its products and technologies, the company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster. Sartorius has also revised its visuals, launched a new logo and consolidated its profile at the subgroup and division levels to underscore its new brand claim.
“Sartorius has evolved over the past 20 years into a different company, especially considering what we have contributed in promoting the development and manufacture of advanced biopharmaceuticals. At the same time, the requirements of our customers worldwide are significantly changing and our competitive environment is also moving,” commented Sartorius CEO and Executive Board Chairman Joachim Kreuzburg.
“The Sartorius brand needs to embed the appropriate key messages in the minds of our customers; namely, that we give them powerful tools to discover and develop medical drugs faster and more simply and to manufacture medications more efficiently. In this way, we are contributing toward accelerating the availability of new medications to a wider range of patients. And, after all, it is also part of our brand promise that we make it easy for our customers to work with us.”
The entire rebranding will take some time to complete as Sartorius has decided on a gradual and environmentally friendly change-over process. Over the next few months, its new brand design will be extended to all Sartorius products. The product brands of both divisions, such as ambr, IncuCyte, BIOSTAT and Cubis, will continue to be used.

Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance